BIOSTAT 1
BIOSTAT 1
BIOSTAT 1
(1st Part)
DR. MD. HABIBUR RAHMAN
MBBS, FCPS P1 (MEDICINE)
BCS (HEALTH)
INTRODUCTION
• Population: Entire group of study elements. Eg. All
doctors in BD
• Sample: part (Subset) of population e.g. 4000 doctors
Observational Experimental
No intervention Intervention given
Less ethical constrain More ethical
More bias Less bias
CASE CONTROL STUDY
• Case- Subject with outcome Control- Subject without outcome
• Advantages:
Good for rare diseases
Good for diseases of long latent period
Little attrition period , Less ethical constrain
Easy to do and less time needed
• Disadvantages:
Bad for rare exposure
Can not measure incidence/ prevalence
Does not prove causality, prone to bias
COHORT STUDY
• Scenario: Obesity & MI ; Hypothesis: Obesity causes MI
• Advantages:
Good for rare exposure, Less prone to bias
Can measure incidence
Can prove causality
• Disadvantages:
Costly and long time needed
Attrition (Loss of follow up)
Not good for rare diseases
CROSS SECTIONAL STUDY
• Scenario: Obesity & MI ; Hypothesis: Obesity causes MI
• Advantages:
Quick and easy, less cost
Can measure prevalence
Generate hypothesis
• Disadvantages:
Can not prove causality
Not goo for rare disease/ rare exposure
Not good for fatal disease/ disease of short duration
RCT
• Inventioned study
• Scenario: RCT with a new anti-hypertensive drug
• Hypothesis: New drug is better than old drug
• Advantages:
Reliable and valid, Can prove causality
Good control of confounders
• Disadvantages:
Expensive and time consuming, ethical constrain
Good internal validity, poor external validity
Non-compliance and attrition